Sun's quarterly U.S. sales dropped 42%, BeiGene offers a public offering of $175 million and the FDA sent a Form 483 to Biocon.

A small drug discovery outfit is challenging one of the world’s largest drugmakers in a cancer drug patent dispute.

GSK will close its Shanghai neuroscience R&D hub, Pfizer and Astellas stopped Xtandi's breast cancer study and more.

Daiichi Sankyo, already losing sales to generics of blockbuster Benicar, has agreed to pay $300 million to settle litigation tied to the drug.

Dr. Reddy's CEO GV Prasad says the generic drugmaker’s top priority is to do what is needed to get its manufacturing up to FDA expectations.

WuXi's small molecule CDMO STA is adding a drug development services operation as it builds itself into an end-to-end CDMO.

There is troubling news for Pfizer and cancer med Xtandi. Pfizer and partner Astellas have given up trials of Xtandi in breast cancer.

Samsung launched Remicade biosimilar, Mitsubishi Tanabe bought NeuroDerm for $1.1 billion, Takeda made a drug discovery deal.

Pharma Asia